^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG CLASS:

Protease inhibitor

9d
Clinical Trial of Gammora® Plus Antiretroviral Treatment for HIV (clinicaltrials.gov)
P2, N=40, Active, not recruiting, Federal University of São Paulo | Recruiting --> Active, not recruiting | Trial completion date: Nov 2025 --> Nov 2026
Enrollment closed • Trial completion date • IO biomarker
|
CD4 (CD4 Molecule)
19d
The impact of ulinastatin on postoperative clinical outcomes in patients with gastric cancer: a retrospective cohort analysis. (PubMed, J Gastrointest Oncol)
Intraoperative UTI attenuates postoperative CRP and ALT elevation, reflecting anti-inflammatory and partial hepatoprotective effects. Integration of UTI into comprehensive perioperative management may enhance clinical recovery.
Clinical data • Retrospective data • Journal
|
CRP (C-reactive protein)
26d
Lopinavir/Ritonavir in PLWH With High-Grade AIN (clinicaltrials.gov)
P1, N=21, Recruiting, University of Wisconsin, Madison | Trial completion date: Jun 2026 --> Jun 2027 | Trial primary completion date: Jun 2026 --> Jun 2027
Trial completion date • Trial primary completion date
28d
COAST Therapy in Advanced Solid Tumors and Prostate Cancer (clinicaltrials.gov)
P1/2, N=76, Recruiting, Medical University of South Carolina | Trial completion date: May 2027 --> May 2028 | Trial primary completion date: May 2026 --> May 2027
Trial completion date • Trial primary completion date
|
dasatinib • sirolimus • metformin • hydroxychloroquine • Viracept (nelfinavir)
2ms
Efficacy and safety of combination therapy with eravacycline versus the Best Available Treatment in patients with severe infection in the department of hematology: a multicenter retrospective study (ChiCTR2600120570)
P=N/A, N=350, Recruiting, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology; Union Hospital, Tongji Medical College, Huazhong University o
New trial
2ms
New trial
2ms
Effects of dietary palygorskite supplementation on production performance and reproductive function of laying hens. (PubMed, Poult Sci)
Compared to those in the control group, the average daily egg production, eggshell thickness, oviduct weight, oviduct index, and the levels of luteinizing hormone, progesterone, and follicle-stimulating hormone were significantly higher in the Pal group...Furthermore, metabolomics analysis revealed that the levels of metabolites such as ritonavir, nicotinate riboside, and inosine were upregulated in the Pal group...These findings indicated that dietary Pal supplementation enhanced the production performance, antioxidant capacity, anti-inflammatory response, and reproductive function of laying hens. Therefore, these findings lay the foundation for the development of strategies and protocols for the inclusion of Pal in the diet of laying hens.
Journal
|
TNFA (Tumor Necrosis Factor-Alpha) • CAT (Catalase) • SOD2 (Superoxide Dismutase 2)
|
ritonavir
3ms
Ulinastatin relieves sepsis-associated dysmotility via IL-1β-related enteric neuroprotection. (PubMed, Eur J Pharmacol)
UTI confers broad and integrated protection of the intestine during sepsis. These findings suggest that IL-1β-mediated inflammatory signaling plays a key role in UTI-induced enteric neuroprotection and restoration of intestinal motility.
Journal
|
IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • CLDN1 (Claudin 1) • IL1B (Interleukin 1, beta)
4ms
NIBAN2/FLII/RREB1 Axis Drives Glioma Stem Cell Malignancy via TLR3 Pathway Activation. (PubMed, Adv Sci (Weinh))
Drug screening identified the HIV protease inhibitor nelfinavir as a specific disruptor of the NIBAN2-FLII complex...Collectively, this study, for the first time, reveals that NIBAN2 maintains GSCs stemness by activating FLII-RREB1 axis and TLR3 signaling, thereby establishing a feed-forward signaling-transcription-metabolism axis. This finding provides a novel strategy and potential targets for precise therapeutic intervention against glioma stemness.
Journal • IO biomarker
|
LDHA (Lactate dehydrogenase A) • CD44 (CD44 Molecule) • SOX2 • TLR3 (Toll Like Receptor 3) • RREB1 (Ras Responsive Element Binding Protein 1)
|
Viracept (nelfinavir)
4ms
NELCER: Radiosensitizing Effect of Nelfinavir in Locally Advanced Carcinoma of Cervix (clinicaltrials.gov)
P3, N=348, Completed, Tata Memorial Hospital | Active, not recruiting --> Completed
Trial completion
|
cisplatin • Viracept (nelfinavir) • ondansetron intravenous
4ms
Potency-enhancing mutations in E3-19K and i-leader increase the cytolytic activity of the PH20/SPAM1-armed oncolytic adenovirus Ad5Δ24RGD. (PubMed, Mol Ther Oncol)
In some cell lines, the fiber modification F5RGD10(2C) or verapamil treatment further improves actual spread efficiency. Nelfinavir inhibits spread and plaque formation of oncolytic adenoviruses with the 19KSS-iLQ125Ter modifications, irrespective of adenovirus death protein (ADP) expression...We identified an insertion site downstream of the L3-23K region that supports relatively high hPH20 activity while preserving the enhanced oncolytic potency of the virus. Combining 19KSS-iLQ125Ter with hPH20 expression may potentially improve therapeutic benefit in glioma.
Journal
|
SPAM1 (Sperm Adhesion Molecule 1)
|
Viracept (nelfinavir)